The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Drug interactions in cancer therapy
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
TAN, P. (2001) · A Clinical Approach to Medicine · doi:10.1142/9789810248178_0024 · Cited by 2,697
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576
Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience
Seidman, A. D., Hudis, C. A., Pierri, M. K., Shak, S., Paton, V. E., Ashby, M. A., Murphy, M., Stewart, S. J., & Keefe, D. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.5.1215 · Cited by 1,563
An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway
Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterström, R. H., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80900-9 · Cited by 1,539
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Ueda, K., Cardarelli, C., Gottesman, M. M., & Pastan, I. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.9.3004 · Cited by 1,063
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications
Lin, J. H., & Yamazaki, M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342010-00003 · Cited by 998
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
Moore, L. B., Goodwin, B., Jones, S. A., Wisely, G. B., Serabjit-Singh, C. J., Willson, T. M., Collins, J. L., & Kliewer, S. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130155097 · Cited by 947
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00003 · Cited by 908
The prevalence of complementary/Alternative medicine in cancer: A systematic review
Ernst, E. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980815)83:4<777::aid-cncr22>3.0.co;2-o · Cited by 891
Identification of a human nuclear receptor defines a new signaling pathway for CYP 3 A induction
Bertilsson, G., Heidrich, J., Svensson, K., Åsman, M., Jendeberg, L., Sydow-Bäckman, M., Ohlsson, R., Postlind, H., Blomquist, P., & Berkenstam, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12208 · Cited by 872
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Changes in plasma protein binding have little clinical relevance
Benet, L. Z., & Hoener, B. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.121829 · Cited by 825
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review
Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadee, W. (2001) · JAMA · doi:10.1001/jama.286.18.2270 · Cited by 705
Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol
Ringel, I., & Horwitz, S. B. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.4.288 · Cited by 677
The Repressed Nuclear Receptor CAR Responds to Phenobarbital in Activating the Human CYP2B6 Gene
Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P., & Negishi, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6043 · Cited by 668
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2971 · Cited by 664
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4
Dürr, D. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.112240 · Cited by 584
Chang, T. K. H., Weber, G. F., Crespi, C. L., & Waxman, D. J. (1993) · PubMed · Cited by 545
The Gut as a Barrier to Drug Absorption: Combined Role of Cytochrome P450 3A and P-Glycoprotein
Zhang, Y., & Benet, L. Z. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140030-00002 · Cited by 518
A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY
JORDAN, V. C., COLLINS, M. M., ROWSBY, L., & PRESTWICH, G. (1977) · Journal of Endocrinology · doi:10.1677/joe.0.0750305 · Cited by 506
Pastan, I., Gottesman, M. M., Ueda, K., Lovelace, E., Rutherford, A. V., & Willingham, M. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.12.4486 · Cited by 484
Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents
Sparreboom, A., Cox, M. C., Acharya, M. R., & Figg, W. D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.182 · Cited by 473
Self-citationEffects of St. John's wort on irinotecan metabolism.
Mathijssen, R. H. J. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.16.1247 · Cited by 457
Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8.
Rahman, A., Korzekwa, K., Grogan, J., Gonzalez, F. J., & Harris, J. W. (1994) · PubMed · Cited by 430
Coezy, E. D., Borgna, J., & Rochefort, H. (1982) · PubMed · Cited by 394
Herbal Modulation of P‐Glycoprotein
Zhou, S., Lim, L. Y., & Chowbay, B. (2004) · Drug Metabolism Reviews · doi:10.1081/dmr-120028427 · Cited by 375
Boesch, D., Gavériaux‐Ruff, C., Jachez, B., Pourtier, A., Bollinger, P., & Loor, F. (1991) · PubMed · Cited by 360
Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma
Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1516 · Cited by 357
Stearns, V., Ullmer, L., Lopez, J. F., Smith, Y., Isaacs, C., & Hayes, D. F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11774-0 · Cited by 354
Kivisto, K., Kroemer, H., & Eichelbaum, M. (1995) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1995.tb05796.x · Cited by 340
High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter
Özvegy-Laczka, C., Hegedűs, T., Várady, G., Ujhelly, O., Schuetz, J. D., Váradi, A., Kéri, G., Őrfi, L., Német, K., & Sarkadi, B. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1485 · Cited by 340
Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice
He, K., Iyer, K. R., Hayes, R. N., Sinz, M., Woolf, T. F., & Hollenberg, P. F. (1998) · Chemical Research in Toxicology · doi:10.1021/tx970192k · Cited by 312
Role of Formulation Vehicles in Taxane Pharmacology
van Zuylen, L., Verweij, J., & Sparreboom, A. (2001) · Investigational New Drugs · doi:10.1023/a:1010618632738 · Cited by 293
Harris, J. W., Rahman, A., Kim, B.-R., Guengerich, F. P., & Collins, J. M. (1994) · PubMed · Cited by 283
Role of Orphan Nuclear Receptors in the Regulation of Drug-Metabolising Enzymes
Wang, H., & LeCluyse, E. L. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00003 · Cited by 278
Takeda, M., Khamdang, S., Narikawa, S., Kimura, H., Hosoyamada, M., Cha, S. H., Sekine, T., & Endou, H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034330 · Cited by 269
The molecular interaction of the high affinity reversal agent XR9576 with P‐glycoprotein
Martin, C., Berridge, G., Mistry, P., Higgins, C., Charlton, P., & Callaghan, R. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702807 · Cited by 258
Effect of St John's wort on imatinib mesylate pharmacokinetics
FRYE, R., FITZGERALD, S., LAGATTUTA, T., HRUSKA, M., & EGORIN, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.06.007 · Cited by 258
Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives
Zhang, W., Ramamoorthy, Y., Kilicarslan, T., Nolte, H., Tyndale, R. F., & Sellers, E. M. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.3.314 · Cited by 249
Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel
Smith, N. F., Acharya, M. R., Desai, N., Figg, II, & Sparreboom, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.8.1867 · Cited by 234
Reversal of multidrug resistance by surfactants
Woodcock, D., Linsenmeyer, M., Chojnowski, G., Kriegler, A., Nink, V, Webster, L., & Sawyer, W. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.217 · Cited by 233
Crewe, H. K., Ellis, S. W., Lennard, M. S., & Tucker, G. T. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(96)00650-8 · Cited by 223
Chang, T. K. H., Yu, L., Maurel, P., & Waxman, D. J. (1997) · PubMed · Cited by 219
Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice.
Edwards, D. J., Bellevue, F. H., & Woster, P. M. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08464-8 · Cited by 217
Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.
Santos, A., Zanetta, S., Cresteil, T., Deroussent, A., Pein, F. J. L., Raymond, É., Vernillet, L., Risse, M., Boige, V., Gouyette, A., et al. (2000) · PubMed · Cited by 213
Hendricks, C. B., Rowinsky, E. K., Grochow, L. B., Donehower, R. C., & Kaufmann, S. H. (1992) · PubMed · Cited by 210
Brada, M., Judson, I., Beale, P., Moore, S., Reidenberg, P., Statkevich, P., Dugan, M., Batra, V, & Cutler, D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690802 · Cited by 208
Hegedűs, T., Őrfi, L., Seprődi, A., Váradi, A., Sarkadi, B., & Kéri, G. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00095-9 · Cited by 207
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth, J. A., Watkins, P. B., Strawderman, M. S., Schott, A. F., Bruno, R., & Baker, L. H. (2000) · PubMed · Cited by 201
Organic anion‐transporting polypeptide (OATP) transporter family and drug disposition
Kim, R. B. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.33.s2.5.x · Cited by 200
Kartner, N., Shales, M., Riordan, J. R., & Ling, V. W. T. (1983) · PubMed · Cited by 199
Burk, O., Koch, I., Raucy, J., Hustert, E., Eichelbaum, M., Brockmöller, J., Zanger, U. M., & Wojnowski, L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404949200 · Cited by 198
The Organic Anion Transporter (OATP) Family
Mikkaichi, T., Suzuki, T., Tanemoto, M., Ito, S., & Abe, T. (2004) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.19.171 · Cited by 191
Drug–drug interactions in oncology: Why are they important and can they be minimized?
Blower, P., de Wit, R., Goodin, S., & Aapro, M. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.03.007 · Cited by 186
Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia
Relling, M. V., Pui, C.-H., Sandlund, J. T., Rivera, G. K., Hancock, M. L., Boyett, J. M., Schuetz, E. G., & Evans, W. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02503-4 · Cited by 183
Kitazaki, T., Oka, M., Nakamura, Y., Tsurutani, J., Doi, S., Yasunaga, M., Takemura, M., Yabuuchi, H., Soda, H., & Kohno, S. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.03.035 · Cited by 182
Grapefruit Juice and Drugs: How Significant is the Interaction?
Bailey, D. G., Arnold, J. M. O., & Spence, J. D. (1994) · Clinical Pharmacokinetics · doi:10.2165/00003088-199426020-00002 · Cited by 175
Does inhibition of P-glycoprotein lead to drug–drug interactions?
Balayssac, D., Authier, N., Cayre, A., & Coudore, F. (2005) · Toxicology Letters · doi:10.1016/j.toxlet.2004.12.008 · Cited by 171
Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects
Dutreix, C., Peng, B., Mehring, G. H., Hayes, M., Capdeville, R., Pokorny, R., & Seiberling, M. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0832-z · Cited by 164
Holmes, F. A., Madden, T., Newman, R. A., Valero, V, Theriault, R. L., Fraschini, G., Walters, R. S., Booser, D. J., Buzdar, A. U., Willey, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2713 · Cited by 164
Köhne, C.-H., Wils, J., Lorenz, M., Schöffski, P., Voigtmann, R., Bokemeyer, C., Lutz, M., Kleeberg, U., Ridwelski, K., Souchon, R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.122 · Cited by 160
Exposure‐Dependent Inhibition of Intestinal and Hepatic CYP3A4 In Vivo by Grapefruit Juice
Veronese, M. L., Gillen, L. P., Burke, J., et al. (2003) · The Journal of Clinical Pharmacology · doi:10.1177/0091270003256059 · Cited by 149
Lepper, E. R., Nooter, K., Verweij, J., Acharya, M. R., Figg, W. D., & Sparreboom, A. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.2.115 · Cited by 142
Self-citationInduction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang, L., Wring, S. A., Woolley, J. L., Brouwer, K. R., Serabjit‐Singh, C. J., & Polli, J. W. (2001) · PubMed · Cited by 142
Ciotti, M., Basu, N. K., Brangi, M., & Owens, I. S. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0453 · Cited by 141
Modulation of Irinotecan Metabolism by Ketoconazole
Kehrer, D. F. S., Mathijssen, R. H. J., Verweij, J., de Bruijn, P., & Sparreboom, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.177 · Cited by 137
Modulation of cytochrome P450 activity: implications for cancer therapy
Scripture, C. D., Sparreboom, A., & Figg, W. D. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70388-0 · Cited by 128
Self-citationPharmacogenomics of the OATP and OAT Families
Marzolini, C., Tirona, R. G., & Kim, R. B. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.273.29831 · Cited by 124
Schurr, E., Raymond, M., Bell, J. C., & Gros, P. (1989) · PubMed · Cited by 122
Functional interaction of intestinal CYP3A4 and P‐glycoprotein
Kivistö, K. T., Niemi, M., & Fromm, M. F. (2004) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00291.x · Cited by 120
Methotrexate and Nonsteroidal Antiinflammatory Drug Interactions
Frenia, M. L., Long, K. S., & Hartshorn, E. A. (1992) · Annals of Pharmacotherapy · doi:10.1177/106002809202600219 · Cited by 118
Interactions Between Antiretrovirals and Antineoplastic Drug Therapy
Antoniou, T., & Tseng, A. L.-I. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544020-00001 · Cited by 117
Machover, D., Schwarzenberg, L., Goldschmidt, E., Tourani, J. M., Michalski, B., Hayat, M., Dorval, T., Misset, J. L., Jasmin, C., Maral, R., et al. (1982) · PubMed · Cited by 117
Swaisland, H., Laight, A., Stafford, L. E., Jones, H., Morris, C. Q., Dane, A. L., & Yates, R. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140040-00005 · Cited by 116
Buggia, I., Zecca, M., Alessandrino, E. P., Locatelli, F., Rosti, G., Bosi, A., Pession, A., Rotoli, B., Majolino, I., Dallorso, A., et al. (1996) · PubMed · Cited by 109
Mier, J. W., Vachino, G., Klempner, M. S., Aronson, F. R., Noring, R., Smith, S., Brandon, E., Laird, W. J. D., & Atkins, M. B. (1990) · Blood · doi:10.1182/blood.v76.10.1933.1933 · Cited by 109
Clinical-Pharmacological Strategies to Assess Drug Interaction Potential During Drug Development
Kuhlmann, J., & ck, W. M. (2001) · Drug Safety · doi:10.2165/00002018-200124100-00001 · Cited by 96
Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40
Tayrouz, Y., Ding, R., Burhenne, J., Riedel, K., Weiß, J., Hoppe‐Tichy, T., Haefeli, W. E., & Mikus, G. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00059-6 · Cited by 94
Vetto, J. T., Papa, M. Z., Lotze, M. T., Chang, A. E., & Rosenberg, S. A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.3.496 · Cited by 89
Dose‐dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL
Martin‐Facklam, M., Burhenne, J., Ding, R., Fricker, R., Mikus, G., Walter‐Sack, I., & Haefeli, W. E. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01595.x · Cited by 87
Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics
Cagnoni, P. J., Matthes, S. G., Day, T., Bearman, S., Shpall, E. J., & Jones, R. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701832 · Cited by 82
Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase
Moran, R. G. (1989) · Cancer · doi:10.1002/1097-0142(19890315)63:6+<1008::aid-cncr2820631303>3.0.co;2-z · Cited by 77
Effects of Ketoconazole on Glucuronidation by UDP-Glucuronosyltransferase Enzymes
Yong, W. P., Ramírez, J., Innocenti, F., & Ratain, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0703 · Cited by 73
KINETICS AND REGULATION OF CYTOCHROME P450-MEDIATED ETOPOSIDE METABOLISM
Zhuo, X., Zheng, N., Felix, C. A., & Blair, I. A. (2004) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)02983-0 · Cited by 70
Effect of Tamoxifen on the Enzymatic Activity of Human Cytochrome CYP2B6
Sridar, C., Kent, U. M., Notley, L. M., Gillam, E. M. J., & Hollenberg, P. F. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.3.945 · Cited by 70
Drug interactions with the taxanes: clinical implications
Baker, A. F., & Dorr, R. T. (2001) · Cancer Treatment Reviews · doi:10.1053/ctrv.2001.0228 · Cited by 69
Papa, M. Z., Vetto, J. T., Ettinghausen, S. E., Mulé, J. J., & Rosenberg, S. A. (1986) · PubMed · Cited by 67
Yoshikawa, M., Ikegami, Y., Sano, K., Yoshida, H., Mitomo, H., Sawada, S., & Ishikawa, T. (2004) · PubMed · Cited by 66
St John’s wort-associated drug interactions: Short-term inhibition and long-term induction?
XIE, H., & KIM, R. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.04.002 · Cited by 64
Jansen, W., Hulscher, T. M., van Ark-Otte, J., Giaccone, G., Pinedo, H. M., & Boven, E. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.58 · Cited by 58
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital
INNOCENTI, F., UNDEVIA, S., RAMIREZ, J., MANI, S., SCHILSKY, R., VOGELZANG, N., PRADO, M., & RATAIN, M. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.07.016 · Cited by 57
Colburn, D. E., Giles, F. J., Oladovich, D., & Smith, J. A. (2004) · Hematology · doi:10.1080/10245330410001701585 · Cited by 54
Veronese, M. L., Sun, W., Giantonio, B. J., Berlin, J. D., Justine Shults, A., Davis, L. E., Haller, D. G., & O'Dwyer, P. J. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602569 · Cited by 51
Lothstein, L., Hsu, S. I., Horwitz, S. B., & Greenberger, L. M. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)71586-x · Cited by 45
Clinical pharmacokinetics of imatinib mesylate.
Levêque, D., & Maloisel, F. (2005) · PubMed · Cited by 34
Uptake and metabolism of vinca alkaloids by freshly isolated human hepatocytes in suspension.
Zhou, X., Placidi, M., & Rahmani, R. (1994) · PubMed · Cited by 34
Wolverton, J. S., Danks, M. K., Schmidt, C., & Beck, W. T. (1989) · PubMed · Cited by 31
A guide to clinically relevant drug interactions in oncology
Lam, M. S., & Ignoffo, R. J. (2003) · Journal of Oncology Pharmacy Practice · doi:10.1191/1078155203jp107oa · Cited by 31
Interstitial Pulmonary Disease Associated with Dyskeratosis Congenita
Dean, R., Nachman, J. B., & Lorenzana, A. (1992) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199221000-00015 · Cited by 31
Evaluation of Aminoglycoside Disposition in Patients Previously Treated with Cisplatin
Christensen, M. L., Stewart, C. F., & Crom, W. R. (1989) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198911000-00003 · Cited by 21
Pharmacokinetics of all-trans-retinoic acid in Japanese patients with acute promyelocytic leukemia.
Usuki (1996) · International Journal of Hematology · doi:10.1016/0925-5710(95)00416-5 · Cited by 8
Swaisland, H., Smith, R. S., Jones, H., et al. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)80728-0 · Cited by 6
Cytochrome P450 and Anticancer Drugs
Ando, Y. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-734-5_14 · Cited by 6
Cited by
The secret ally: immunostimulation by anticancer drugs
Galluzzi, L., Senovilla, L., Zitvogel, L., & Kroemer, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3626 · Cited by 670
Bae, Y., & Kataoka, K. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.016 · Cited by 669
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Recent Advances in the Application of Vitamin E TPGS for Drug Delivery
Yang, C., Wu, T., Qi, Y., & Zhang, Z. (2018) · Theranostics · doi:10.7150/thno.22711 · Cited by 402
Therapeutic Applications of Herbal Medicines for Cancer Patients
Yin, S.-Y., Wei, W.-C., Jian, F.-Y., & Yang, N.-S. (2013) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2013/302426 · Cited by 384
Metadata
- Authors
- Scripture, C. D., & Figg, W. D.
- Venue
- Nature Reviews Cancer
- Published
- 2006-07-01
- Volume
- 6
- Issue
- 7
- Pages
- 546-558
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2000001421
- Cited by
- 366
- References
- 110
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.